Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand

Punnee Pitisuttithum*, Supachai Rerks-Ngarm, Valai Bussaratid, Jittima Dhitavat, Wirach Maekanantawat, Swangjai Pungpak, Pravan Suntharasamai, Sirivan Vanijanonta, Sorachai Nitayapan, Jaranit Kaewkungwal, Michael Benenson, Patricia Morgan, Robert J. O'Connell, Jeffrey Berenberg, Sanjay Gurunathan, Donald P. Francis, Robert Paris, Joseph Chiu, Donald Stablein, Nelson L. MichaelJean Louis Excler, Merlin L. Robb, Jerome H. Kim

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

43 Scopus citations

Fingerprint

Dive into the research topics of 'Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand'. Together they form a unique fingerprint.

Medicine & Life Sciences

Agriculture & Biology

Chemistry